Skip to main content

Table 4 Occurrence rate of bleeding (safety endpoint)

From: Comparison of rivaroxaban and parnaparin for preventing venous thromboembolism after lumbar spine surgery

Bleeding events Rivaroxaban group Parnaparin group P value
Any bleeding during the treatment 21 (6.2 %) 17 (5.2 %) >0.5
Severe bleeding 2 (0.6 %) 1 (0.3 %) >0.25*
Fatal bleeding 0 0  
Bleeding into important organs 1 0  
Reoccurrence of surgical bleeding 1 0  
Clinically obvious bleeding outside the surgical site 0 1  
Induced hemoglobin decreasing 0 0  
Induced blood transfusion ≥2 units 0 0  
Non-severe bleeding 19 (5.6 %) 16 (4.9 %) >0.5
Clinically related non-severe bleedinga 6 6  
Bleeding incision complicationsb 7 4  
Other non-severe bleeding 6 6  
  1. *Used Fisher’s exact test
  2. aClinically related non-severe bleeding included multi-sites bleeding, spontaneous hematoma and big incision hematoma
  3. bBleeding incision complications was the combined indicator of big incision bleeding and surgical site bleeding